ALK-Abello A/S Announces Positive Outcome of Pivotal Phase III Trial With New Allergy Immunotherapy Tablet Against House Dust Mite Allergy
6/19/2013 9:28:09 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ALK announces positive outcome of the first of two pivotal Phase III trials with its new allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases. The MERIT trial meets its primary endpoint and demonstrates that the new treatment has a significant clinical effect in allergic rhinitis. The positive outcome allows for a European filing in 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by